

GLAXOSMITHKLINE PLC
Form 6-K
December 04, 2009

FORM 6-K

**SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549**

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For period ending December 2009

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

--

Financial Services Authority

GlaxoSmithKline plc received on 4 December 2009 from BlackRock, Inc a notification of interests in GlaxoSmithKline plc Ordinary shares of 25 pence each, dated on 1 December 2009. This notice is given in accordance with DTR 5.8.12.

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES¹

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:ⁱⁱ

GLAXOSMITHKLINE
PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares

already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation:ⁱⁱⁱ

BlackRock, Inc

4. Full name of shareholder(s)

(if different from 3.):^{iv}

5. Date of the transaction and date on which the threshold is crossed or reached:^v

1st December 2009

6. Date on which issuer notified:

3rd December 2009

7. Threshold(s) that is/are crossed or reached:^{vi, vii}

Holding has gone above 5%

8. Notified details:

A: Voting rights attached to shares^{viii, ix}

Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction		Resulting situation after the triggering transaction		
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights	% of voting rights ^x
GB0009252882	N/A	N/A	Direct N/A	Indirect ^{xii} N/A 329,124,508	Direct 6.4%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument	Expiration date ^{xiii}	Exercise/ Conversion Period ^{xiv}	Number of voting rights that may be acquired if the instrument is exercised/ converted.	% of voting rights
------------------------------	---------------------------------	--	---	--------------------

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ^{xv}

Resulting situation after the triggering transaction

Type of financial instrument	Exercise price	Expiration date ^{xvii}	Exercise/ Conversion period ^{xviii}	Number of voting rights instrument refers to	% of voting rights ^{xix} , ^{xx}
CFD	N/A	N/A	N/A	3,113,781	Minimal 0.06%

Total (A+B+C)

Number of voting rights 332,238,289	Percentage of voting rights 6.40%
--	--------------------------------------

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: ^{xxi}

On 1 December 2009, the Barclays Global Investors (BGI) business was acquired by BlackRock, Inc. The combined holdings of BlackRock, Inc. following this acquisition triggered this disclosure requirement

BlackRock Investment Management (UK) Limited - 332,238,289 (6.40%)

Proxy Voting:

10. Name of the proxy holder:	N/A
11. Number of voting rights proxy holder will cease to hold:	N/A
12. Date on which proxy holder will cease to hold	N/A

voting rights:

13. Additional information:

BlackRock Compliance Disclosures Team

14. Contact name:

Stuart Watchorn

15. Contact telephone number:

020 7743 5741; stuart.watchorn@blackrock.com

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: December 04 2009

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc